2029 Pharma Sales 
Clarivate
JANUARY 8, 2024
Clarivate data indicates a 90% probability that datopotamab deruxtecan will win marketing authorization in the United States, and projects 2029 sales of $2.7 billion in 2029 for CASGEVY alone. FDA accelerated approval in August, Clarivate projects the drug will see $850 million in sales by 2029. Granted U.S.
Pharmaceutical Technology
APRIL 24, 2023
According to GlobalData’s Pharma Intelligence Centre, a sales consensus forecasts Brukinsa to have global sales of $3.98 billion in 2029, while Calquence is expected to make $5.31 While Imbruvica sales were $3.78 billion in 2029. While Imbruvica sales were $3.78 billion in 2029.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
MAY 10, 2023
According to a consensus forecast from GlobalData’s Pharma Intelligence Centre, Descovy is estimated to yield $1.83 billion in global sales in 2029, while Truvada estimates amount to $30 million. Truvada has since gone generic, with Teva Pharmaceuticals launching the first FDA-approved Truvada generic in October 2020.
Pharmaceutical Technology
MAY 16, 2023
trillion in Q1 2023, according to GlobalData’s pharma intelligence centre companies database. This growth is expected to continue, with a 62% growth in annual consensus sales forecast from 2023 to 2028, fuelled by the company’s semaglutide portfolio, according to GlobalData’s report, ‘Looking ahead to 2023 – the future of pharma’.
European Pharmaceutical Review
JANUARY 18, 2024
In its report on the insomnia market published last month, GlobalData expected that sales for DORAs, which offer a new mechanism of action for the condition, will continue to grow at a CAGR of 8.6 million in sales by 2032. million in sales by 2032. percent sales expected in 2032 within the seven major markets.
pharmaphorum
SEPTEMBER 30, 2022
7,326,708) was challenged by Mylan Pharma, now Viatris, before the US Patent and Trademark Office (USPTO), which ruled in Merck’s favour last year. 8,414,921), which covers the co-formulation of sitagliptin and metformin and is due to expire in 2029. The US patent (No. billion in the first half of 2022.
Pharmaceutical Technology
MAY 23, 2023
According to a consensus forecast from GlobalData’s Pharma Intelligence Centre, Lumakras, also known as sotorasib, has projected sales of $1.47 billion in 2029. In May 2021, Amgen’s Lumakras was approved for use in adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
Expert insights. Personalized for you.
59 
Let's personalize your content